This site makes use of Javascript, please enable your web browser to allow Javascript. Thank you.
Alumni | RSS | AA | Languages
 

RSS Feeds

RSS Feed - Life Sciences - Patent Litigation - Kaye Scholer LLP

Current Feed: http://www.kayescholer.com/practice/rss.xml?p=life_sciences_patent

> Change Feed

Gerald Sobel (10/28/14)

Gerald Sobel is an experienced litigator whose practice is primarily in the areas of patent, antitrust and agreements. He is also active in mediation. 

Another District Court Holds That “Reverse Payment” Means Cash Under FTC v. Actavis (10/24/14)

District Court Precludes Defense Based on Strength of Patent in FTC v. Cephalon “Reverse Payment” Litigation (10/24/14)

EC Imposes $580 Million Fine for Alleged Actions to Prevent or Delay Generic Entry (10/24/14)

District Court Holds That Under FTC v. Actavis, “Pay for Delay” Means Money (10/23/14)

Supreme Court Lets So-Called "Reverse Payment" Stand (10/10/14)

Aaron Stiefel (09/30/14)

Aaron Stiefel, Co-Chair of the Intellectual Property Department, has represented leading research-based pharmaceutical and biotechnology companies, such as Pfizer Inc, and Novartis, in all aspects of complex patent litigations. His experience includes bringing and defending patent infringement actions concerning antibiotics, antihypertensives, antifungal medications, treatments for erectile dysfunction, the cloning of alpha-interferon, testing of blood for hepatitis C infection, monoclonal antibodies, contact lenses, surgical devices, methods for producing transgenic mice and data storage products. Aaron litigates against other research-based companies and has also litigated claims brought against generic drug manufacturers under the Hatch-Waxman Act. Aaron has counseled clients with respect to a host of patent law issues and has authored articles and lectured on patent law. Aaron has also represented pharmaceutical companies regarding false advertising and unfair competition claims. Aaron was recently recognized as an “IP Star” by Managing IP Handbook 2014, recommended by The Legal 500 United States 2013 and ranked in IAM Patent 1000 2014 for his work in patent litigation.

Daniel P. DiNapoli (09/24/14)

Daniel DiNapoli concentrates his practice in patent, trade secret, and unfair competition litigation and counseling. His intellectual property practice includes litigation, arbitration, and advice regarding patents and trade secrets in biotechnology, pharmaceuticals, ANDA litigations, including ANDA litigation involving Pfizer’s blockbuster drugs Viagra® and Celebrex®, medical diagnostics, surgical devices, computers, computer software, and telecommunications.  Dan was recently recognized as an “IP Star” by Managing IP Handbook 2014 and recommended by The Legal 500 United States 2013. He has also been named by Best Lawyers in America as Lawyer of the Year for 2012 in the New York City area in the field of biotechnology, by The American Lawyer Magazine as Litigator of the Month, by The American Lawyer Litigation Daily as Litigator of the Week, and by the 2011 Who’s Who Legal for life sciences in New York. He has been ranked in Best Lawyers in America in biotechnology law since 2008.

Sylvia M. Becker (09/24/14)

Sylvia Becker concentrates her practice in intellectual property litigation, including the representation of major pharmaceutical companies in complex patent cases. Sylvia is fluent in both German and French.

Kaye Scholer Wins Four LMG Life Sciences Awards (09/24/14)

Subscribe

 
 
Practice Practice Groups Industry Groups Regional Groups Pro Bono Professionals Firm Careers Diversity Newsroom Events Offices